Figure 2.
Overall surival (OS) (A); and cumulative incidence of NRM (B) in autologous HCT recipients with TA-TMA (n = 24) vs those without- TA-TMA (n = 107). (A) OS was significantly lower for children with TA-TMA (n = 24; 1-year OS: 74.3% ± 10.2%) vs those with no TA-TMA (n = 107; 1-year OS: 90.9% ± 3.1%). (B) NRM was significantly higher for TA-TMA patients (n = 24; 1-year NRM: 18.9% ± 8.8%) vs those with no TA-TMA (n = 107; 1-year NRM: 1.1% ± 1.1%).

Overall surival (OS) (A); and cumulative incidence of NRM (B) in autologous HCT recipients with TA-TMA (n = 24) vs those without- TA-TMA (n = 107). (A) OS was significantly lower for children with TA-TMA (n = 24; 1-year OS: 74.3% ± 10.2%) vs those with no TA-TMA (n = 107; 1-year OS: 90.9% ± 3.1%). (B) NRM was significantly higher for TA-TMA patients (n = 24; 1-year NRM: 18.9% ± 8.8%) vs those with no TA-TMA (n = 107; 1-year NRM: 1.1% ± 1.1%).

Close Modal

or Create an Account

Close Modal
Close Modal